Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808276 | 1.00 | HRH3 (0.51) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL25081503 | 0.89 | HRH3 (0.42) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL25081529 | 0.89 | HRH3 (0.42) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL25125333 | 0.84 | HRH3 (0.39) | HRH3 | |
| SCHEMBL25081887 | 0.83 | HRH3 (0.40) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL12122183 | 0.82 | HRH3 (0.53) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL16000539 | 0.82 | HRH3 (0.53) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL16000538 | 0.82 | HRH3 (0.53) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL22996703 | 0.81 | HRH3 (0.49) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL24498744 | 0.81 | HRH3 (0.51) | HRH3CHRM2HTR1ADRD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | HRH3 1367/4885CHRM2 3474/4885HTR1A 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.